51st week of 2014 patent applcation highlights part 38 |
Patent application number | Title | Published |
20140369939 | COMPOSITIONS FOR DETECTING ANALYTES BY MAGNETIC RESONANCE IMAGING - Injectable compositions for the MRI detection of an analyte selected from the group consisting of reactive oxygen species, proteases and enzymes, comprising
| 2014-12-18 |
20140369940 | Anti-Alpha Synuclein Binding Molecules - Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 2014-12-18 |
20140369941 | Oral Care Compositions - Described herein are aqueous oral compositions comprising cationic steroidal compound and a quaternary ammonium compound; and methods for making and using the same. | 2014-12-18 |
20140369942 | COMPOSITION COMPRISING TAUROURSODEOXYCHOLIC ACID - Provided is a method for preventing or treating a periodontal disease; or a method for improving oral hygiene, including administering a pharmaceutical composition containing tauroursodeoxycholic acid as an active ingredient. | 2014-12-18 |
20140369943 | COMPOSITIONS COMPRISING ISOSORBIDE MONOESTERS AND HALOGENATED ANTIMICROBIAL ACTIVE COMPOUNDS - What are described are compositions comprising
| 2014-12-18 |
20140369944 | EASILY APPLIABLE, STORAGE STABLE, RADIATION-CURABLE, PIGMENTED, ARTIFICIAL NAIL GEL COATINGS - Limited shelf life due to pigment settling and the formation of hard packs in pigmented UV curable nail gels is solved by the present invention which describes a composition, method, and use of a UV curable, thixotropic, radiation curable, low viscosity gel comprised of a formulation containing thixotropic additive(s) and in some cases dispersants for additional dispersion stability. The thixotropic pigmented gel has prolonged shelf life and long time storage at ambient conditions. It also contains negligible amounts of unreactive solvent. The thixotropic additive also changes the rheological properties of the gel, which allows the nail gel to be easily applied to nails at a lower viscosity due to shear thinning. | 2014-12-18 |
20140369945 | APPARATUS AND METHODS FOR CONCEALING VITILIGO - A method for concealing vitiligo is provided. The method comprises depressing a spring head. The spring head may be covered by a covering. Depression of the spring head may saturate the covering with a solution. The solution may include a bronzer and dihydroxyacetone (“DHA”). The method may also comprise guiding the saturated covering over a portion of depigmented skin. | 2014-12-18 |
20140369946 | PRODUCT FOR KERATIN-CONTAINING FIBERS, CONTAINING AT LEAST A SPECIFIC COPOLYMER OF THE N-VINYLPYRROLIDONE AND AT LEAST A POLYMER WITH STRUCUTRAL UNITS DERIVED FROM MALEIC ACID ESTER - Agents for treating keratin-containing fibers, in particular human hair, and methods for the use of such agents are provided. The agent includes at least one copolymer (a) and at least one copolymer (b). The copolymer (a) includes at least one structural unit of a formula (I) and at least one structural unit of a formula (II). Copolymer (b) includes at least one structure unit of formula (AI) and at least one structural unit of formula (A2). The agent is contained in a cosmetically acceptable carrier. | 2014-12-18 |
20140369947 | COSMETIC COMPOSITION COMPRISING AN ANIONIC OR NONIONIC ASSOCIATIVE POLYMER, FIXING POLYMER AND A PARTICULAR SURFACTANT - The present invention relates to a cosmetic composition, especially a hair composition, comprising at least one anionic or nonionic associative polymer, at least one fixing polymer and at least one nonionic surfactant comprising predominantly fatty chains having from 8 to 14 carbon atoms, the weight content of nonionic surfactants comprising predominantly fatty chains having from 8 to 14 carbon atoms in the composition being greater than or equal to 2%. | 2014-12-18 |
20140369948 | AGENT FOR KERATINOUS FIBRES, CONTAINING AT LEAST ONE SPECIFIC AMPHIPHILIC CATIONIC POLYMER AND AT LEAST ONE SPECIFIC COPOLYMER - An agent for treating keratinous fibres, in particular human hair, containing in a cosmetically acceptable carrier (a) at least one amphiphilic, cationic polymer, comprising in each case at least one structural unit of formulae (I) to (IV), wherein R | 2014-12-18 |
20140369949 | Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor - A cosmetic treatment method, and a device therefor, are provided that allow for cosmetic treatment of cosmetic disorders, caused by chronological age, environmental factors, changes in physiological functions of skin, such as psoriasis, dermatitis, acne, cellulites, and viral and/or bacteriological attacks. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the area to be cosmetically treated, such that a cosmetic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said cosmetic dosage of nitric oxide (NO). Furthermore, a manufacturing method for said device is provided. | 2014-12-18 |
20140369950 | Gel-Based Lipstick Having Improved Rheology - Gel-based lipstick compositions are disclosed comprising an ester terminated poly(ester-amide) (ETPEA) polymeric gellant, a first wax component having a melting point above the sol-gel transition temperature of the ETPEA gellant, a second wax compositions having a melting point equal to of below the sol-gel transition temperature of the ETPEA gellant, optionally a silicone T-resin co-gellant, and one or more oils capable of forming a gel with the ETPEA gellant. The gel compositions are solid or semi-solid at room temperature and are capable of being molded into self-supporting sticks. The disclosed gels provide high gloss films when applied to the lips and/or provide a rheology characterized by a high viscosity over repeated shear cycles. | 2014-12-18 |
20140369951 | OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE - A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. | 2014-12-18 |
20140369952 | BIODEGRADABLE MEDICAL ADHESIVE AND PREPARATION METHOD AND USE THEREOF - A medical adhesive with good biodegradable performance capable of undergoing crosslinking copolymerization, comprising a mono-alpha-cyanoacrylate and a bis-alpha-cyanoacrylic acid diol ester monomer molecule. The olefinic bonds in the mono-alpha-cyanoacrylate structure are polymerized in the presence of infinitesimal anions to form a solid 3D high polymer; the 3D high polymer is provided with degradation sites on the web-like backbone chain, with clear degradation path and absorbable degradation products. The medical adhesive can be used for wound adhesive, large area wound hemostasia, and visceral and soft tissue wound closure. | 2014-12-18 |
20140369953 | Enhancing the Antimicrobial Activity of Biocides with Polymers - Disclosed are compositions comprising a) an antimicrobial agent, which is selected from the group consisting of biocides containing halogen atoms and/or containing phenolic moieties, formic acid, chlorine dioxide, chlorine dioxide generating compounds, dialdehydes; components containing an antimicrobial metal such as antimicrobial silver, and b) a polyamine, especially a polyethylenimine. The polyamine is effective as a booster for the antimicrobial agent. | 2014-12-18 |
20140369954 | D, L-CYCLIC PEPTIDE NANOTUBE REINFORCING AGENTS - The disclosed subject matter can provide a nanotube-reinforced polymer composite material comprising a plurality of nanotubes, each nanotube being formed of a plurality of cyclic peptide molecules, disposed within a polymer matrix, such as a biodegradable polymer matrix. A cyclic polymer, such as a cyclic 8-mer, composed of amino acid residues of alternating absolute configurations (D/L, R/S), can self-assemble into nanotubes useful for preparation of the composite polymer material of the invention. For example, the cyclic peptide (QL)4, wherein the glutamine and leucine residues are of opposite absolute configuration, self-assembles into nanotubes, which when formed into a reinforced polymer composite including poly(caprolactone), provides a biocompatible material of greater tensile strength and Young's modulus compared to the poly(caprolactone) material alone. The nanotubes can be prepared by a vapor equilibration technique or by a solvent-nonsolvent precipitation technique. The materials of the invention can be used for implants, stents and the like as well as for synthetic ligaments, tendons, cartilage, and bone for use in the living tissue of a patient in need thereof. For example, a spinal fusion cage comprising a PDLLA polymer matrix with a plurality of nanotubes of the invention can exhibit enhanced stiffness. | 2014-12-18 |
20140369955 | METHODS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×10 | 2014-12-18 |
20140369956 | CONJUGATES OF GM-CSF AND IL-7, COMPOSITIONS AND METHODS RELATED THERETO - In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids. | 2014-12-18 |
20140369957 | COMBINATION OF GROWTH FACTORS, CYTOKINES, ANTIBACTERIAL/ANTIVIRAL FACTORS, STEM CELL STIMULATING FACTORS, COMPLEMENT PROTEINS C3A/C4A, IMMUNOGLOBULINS AND CHEMOTACTIC FACTORS - The present invention refers to a combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins C3a/C4a, immunoglobulins and chemotactic factors. The invention also relates to a process for the preparation of said combination from serum, placenta or colostrum and to composition containing said combination for use in the treatment of conditions requiring tissue repair and regeneration and for the substitution of stem cell therapies. | 2014-12-18 |
20140369958 | IL-12 FOR RADIATION PROTECTION AND RADIATION-INDUCED TOXICITY MITIGATION - Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma. | 2014-12-18 |
20140369959 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION - The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds. | 2014-12-18 |
20140369960 | CONJUGATED BIOLOGICAL MOLECULES AND THEIR PREPARATION - Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X′ represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X′ and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z | 2014-12-18 |
20140369961 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE - The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention. | 2014-12-18 |
20140369962 | METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS - It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function. | 2014-12-18 |
20140369963 | METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS - It is disclosed a method for the treatment of hepatitis B (HBV) infection or HBV/hepatitis D (HDV) co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function. | 2014-12-18 |
20140369964 | GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon β activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon β activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments. | 2014-12-18 |
20140369965 | BIFIDOBACTERIUM CECT 7765 AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF OVERWEIGHT, OBESITY AND ASSOCIATED PATHOLOGIES - The present invention relates to the | 2014-12-18 |
20140369966 | PREVENTIVE AND/OR AMELIORATIVE AGENT FOR DISEASES, STAMINA ENHANCEMENT AGENT, ANTI-FATIGUE AGENT, AND PHARMACEUTICAL AND FOOD AND DRINK USING THEM - A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria. The purple non-sulfur bacteria includes | 2014-12-18 |
20140369967 | METHOD OF EXPANDING HEMATOPOIETIC STEM CELLS - Described is a method of expanding hematopoietic stem or progenitor cells. The invention further includes a method of treating primary or secondary bone marrow failure syndrome. | 2014-12-18 |
20140369968 | GENERATING VASCULOGENIC CELL POPULATIONS - The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine. | 2014-12-18 |
20140369969 | METHODS FOR TREATING CONDITIONS BY RESTORING CENTRAL NERVOUS SYSTEM ENDOCRINE GLAND FUNCTION, AND COMPOSITIONS AND DEVICES FOR PRACTICING THE SAME - Methods of improving a condition in a subject are provided herein. Aspects of the methods include at least partially restoring normal function of a central nervous system endocrine gland in a manner sufficient to improve the condition in the subject. In some instances, the condition is an aging associated condition. Aspects of the invention further include compositions, systems and devices for practicing the methods. | 2014-12-18 |
20140369970 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE - Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration. | 2014-12-18 |
20140369971 | METHOD AND COMPOSITION FOR INDUCING HUMAN PLURIPOTENT STEM CELLS - The present invention provides a fibromodulin (FMOD) reprogrammed (FReP) cell and a method of making therefor, a culture medium therefor, and a supernatant thereof, and methods of making and using these. | 2014-12-18 |
20140369972 | ENHANCED STEM CELL COMPOSITION - The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution. | 2014-12-18 |
20140369973 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS - The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits. | 2014-12-18 |
20140369974 | COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT USING SPECIFIC PROTOCOLS FOR T/B CELL DEPLETION - A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methos comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject. | 2014-12-18 |
20140369975 | BIOMATERIALS COMPRISING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMER MOLECULES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS - The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides that is tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA. The biocompatible polymers are modified to contain a crosslinking group so that the HA can be incorporated into a scaffold and retained in place. The novel biomaterial | 2014-12-18 |
20140369976 | METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO - Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes. | 2014-12-18 |
20140369977 | Targeting Tumor Neovasculature with Modified Chimeric Antigen Receptors - A T cell transduced with a chimeric antigen receptor can be administered to a host to kill cancer cells. The chimeric antigen receptor can include a targeting moiety with a strong binding affinity to α | 2014-12-18 |
20140369978 | GDF-5 MUTANT FOR INDUCING CARTILAGE FORMATION - The present invention is directed to GDF-5 related proteins having an improved capability of inducing cartilage formation and a reduced capability of inducing bone formation. The novel proteins are particularly useful in the treatment of cartilage defects, wherein the formation of bone tissue is undesirable. | 2014-12-18 |
20140369980 | METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION - Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins. | 2014-12-18 |
20140369981 | protective effects and application of a Lactobacillus plantarum on the alleviation of lead toxicity | 2014-12-18 |
20140369982 | PREBIOTIC AND PRESERVATIVE USES OF OIL EMULSIFIED PROBIOTIC ENCAPSULATIONS - An encapsulation system is provided comprising nitrogen-purge, instant bonding encapsulation method. Specifically, the encapsulation system comprises a composition, a two-piece capsule comprising a capsule cap and a capsule body; a gas to purge oxygen from the composition within the capsule; and a sealing solution to seal the capsule cap to the capsule body. Associated methods for encapsulating compositions using the encapsulation system are also provided. | 2014-12-18 |
20140369983 | ISCHEMIC TISSUE CELL THERAPY - The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina. | 2014-12-18 |
20140369984 | BIOMATERIAL FOR ARTICULAR CARTILAGE MAINTENANCE AND TREATMENT OF ARTHRITIS - The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery. | 2014-12-18 |
20140369985 | REMOVAL OF TUMOR CELLS FROM INTRAOPERATIVE AUTOLOGOUS BLOOD SALVAGE - The invention relates to a method performed ex vivo for removal of tumor cells from intraoperatively collected blood salvage, to antibodies and scaffold proteins which mimic antibodies for use in said ex vivo method, to the use of said ex vivo method for removal of tumor cells from intraoperatively collected blood salvage followed by reintroducing the so obtained purified blood salvage or of concentrates of erythrocytes purified by said method to a patient from whom said intra-operatively collected blood was obtained, as well as to blood salvage or a concentrate of erythrocytes, both obtainable by said method for reinfusion to said patient. | 2014-12-18 |
20140369986 | PHAGE DERIVED ANTIMICROBIAL ACTIVITIES - The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. | 2014-12-18 |
20140369987 | DERMASEPTIN B2 USED AS AN INHIBITOR OF THE GROWTH OF A TUMOR - The invention relates to the use of peptides corresponding to dermaseptin B2 or fragments thereof for treating proliferative diseases such as cancer or ocular lesions, and to pharmaceutical compositions containing such peptides. | 2014-12-18 |
20140369988 | Novel Toxin-Antitoxin System - Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU. | 2014-12-18 |
20140369989 | METHODS AND COMPOSITIONS FOR REDUCING THE ENVIRONMENTAL IMPACT OF ANIMAL WASTE - Methods for reducing the environmental impact of animal waste are described. In particular embodiments, the methods comprise administering to an animal an enzyme, such as alkaline phosphatase, that is effective to reduce the amount of a detrimental compound, such as ammonia or phosphorous, that is present in or released from animal waste. Also provided is a method for increasing phosphorus digestion in an animal. Compositions suitable for use in such methods are also described. | 2014-12-18 |
20140369990 | TARGETED ANTIMICROBIALS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Targeted antimicrobials are described and related, compositions, methods and systems. | 2014-12-18 |
20140369991 | Formulations for Wound Therapy - The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention. | 2014-12-18 |
20140369992 | C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses - The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins. | 2014-12-18 |
20140369993 | STABILISED PROTEIN COMPOSITIONS BASED ON SEMIFLUORINATED ALKANES - The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route. | 2014-12-18 |
20140369994 | METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS - Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia. | 2014-12-18 |
20140369995 | COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION - The present invention provides compositions and methods for treating stroke patients using TCM and a Western medicament used for the treatment of stroke patients. | 2014-12-18 |
20140369996 | Chymosin for the Prevention and Treatment of Gastrointestinal Disorders - The present invention is directed to medical or dietary treatments comprising administration of a zymogen such as chymosin or other rennins. Embodiments of the invention are directed to treating infant colic, heartburn, gastro-esophageal reflux (GER), gastro-esophageal reflux disease (GERD), irritable bowel syndrome, and recurrent abdominal pain. The invention is also directed to improving absorption of calcium from milk for osteoporosis patients. Further the present invention may have a very positive effect on life quality for groups with different chronic digestion problems such as ulcerous colitis, multiple sclerosis, migraines, weight disorders and diabetes. Infants may be given several drops of a composition containing chymosin prior to every feeding, regardless of whether they are bottle or breast-fed. The composition containing chymosin can also be incorporated into a food product such as drinking milk or baby formula. The rennin helps infants break down milk proteins so that the milk can be transformed into cheese pulp in the stomach, mimicking the process occurring in the stomachs of normal infants. | 2014-12-18 |
20140369997 | Pharmaceutical composition for a foaming eye drop - The present application describes a method of creating a foaming ophthalmic formulation. The described formulation includes the addition of a foaming agent. The resulting solution is designed to be distributed by a non-aerosol foaming bottle/or aerosol. | 2014-12-18 |
20140369998 | Biomarkers for Tuberculosis and HIV/AIDS - Described herein is a diagnostic test that identifies circulating biomarkers for the differentiation and classification of the pathogenesis of TB and/or HIV in a population. | 2014-12-18 |
20140369999 | SCREENING METHOD - This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient. | 2014-12-18 |
20140370000 | STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH - The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration. | 2014-12-18 |
20140370001 | IgE ANTIBODIES FOR THE INHIBITION OF TUMOR METASTASIS - The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor. | 2014-12-18 |
20140370002 | METHODS FOR THE TREATMENT OF GOUT - Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2014-12-18 |
20140370003 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF - The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products. | 2014-12-18 |
20140370004 | METHOD OF BOOSTING THE IMMUNE RESPONSE IN NEONATES - In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71 | 2014-12-18 |
20140370005 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS - The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent. | 2014-12-18 |
20140370006 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS - The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent. | 2014-12-18 |
20140370007 | METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF - This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue. | 2014-12-18 |
20140370008 | THROMBIN-BINDING ANTIBODY MOLECULES AND USES THEREOF - This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin. | 2014-12-18 |
20140370009 | THERAPEUTIC NANOPARTICLES AND METHODS OF USE THEREOF - Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell (e.g., miR-10b) or a sequence within an mRNA encoding a pro-apoptotic protein that is covalently linked to the nanoparticle. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject. | 2014-12-18 |
20140370010 | TREATMENT OF LEUKEMIAS AND CHRONIC MYELOPROLIFERATIVE DISEASES WITH ANTIBODIES TO EPHA3 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders. | 2014-12-18 |
20140370011 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES - The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders. | 2014-12-18 |
20140370012 | FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS - The present invention relates to biologically active fusion proteins containing the IgG2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins. | 2014-12-18 |
20140370013 | NOVEL HETERODIMERIC PROTEINS - The invention provides novel heterodimeric proteins including heterodimeric antibodies. | 2014-12-18 |
20140370014 | USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY - Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 2014-12-18 |
20140370015 | USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY - Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 2014-12-18 |
20140370016 | SPARC BINDING SCFVS - The invention provides compositions comprising SPARC binding ScFc and its use. | 2014-12-18 |
20140370017 | Methods for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 2014-12-18 |
20140370018 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 2014-12-18 |
20140370019 | BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE - The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2014-12-18 |
20140370020 | ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN - It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH 1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain. | 2014-12-18 |
20140370021 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2014-12-18 |
20140370022 | ANTIBODIES CROSS-REACTIVE TO HUMAN AND MOUSE c-Met AND USES THEREOF - The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers. | 2014-12-18 |
20140370023 | ERG MONOCLONAL ANTIBODIES - Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting. The antibodies can also be used to inhibit the activity of ERG or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript and to treat malignancies associated with overexpression of ERG or an ERG fusion event, such as prostate cancer, Ewing's sarcoma, acute myeloid leukemia, acute T-lymphoblastic leukemia, endothelial cancer, and colon cancer. | 2014-12-18 |
20140370024 | Methods of Treating Pain by Inhibition of VGF Activity - The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of screening for said inhibitors. | 2014-12-18 |
20140370025 | USES OF MAMMALIAN CYTOKINES AND AGONISTS; RELATED REAGENTS - Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor. | 2014-12-18 |
20140370026 | Cytomegalovirus Surface Protein Complex For Use in Vaccines and as a Drug Target - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pULl28or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection. | 2014-12-18 |
20140370027 | INHIBITION OF MACROPHAGE-SYNTHESIZED WNT7B TO INHIBIT TUMOR ANGIOGENESIS AND METASTASIS - The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor. | 2014-12-18 |
20140370028 | DIAGNOSIS AND TREATMENT OF VIRAL DISEASES - This disclosure relates to methods of diagnosing a viral disease such as idiopathic pulmonary fibrosis, Castleman's disease, a lymphoma, a thymoma or a sarcoma in a patient by identifying one or more virus-specific elements such as a nucleic acid or a viral protein or a patient antibody to a virus-specific element, as well as to kits for diagnosing the viral disease in a patient. The disclosure further relates to methods of monitoring disease progression and/or the efficacy of therapy by measuring the levels of a virus-specific element in a sample from a patient. In addition, the disclosure relates to methods of identifying therapeutic agents that show efficacy in reducing levels of virus-specific agents in vitro. The disclosure further relates to methods of treating idiopathic pulmonary fibrosis, a lymphoproliferative disease and cancer, as well as to methods of preventing viral infection, including Herpesvirus saimiri infection. | 2014-12-18 |
20140370029 | METHOD FOR PREDICTING RESPONSIVENESS TO A TREATMENT WITH AN EGFR INHIBITOR - The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor. | 2014-12-18 |
20140370030 | ANTIBODIES ANTI-SPLA2-X AND USES THEREOF - The present invention relates to isolated antibodies against human sPLA2-X and uses thereof. | 2014-12-18 |
20140370031 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 2014-12-18 |
20140370032 | Multi-strain-reactive Antibodies for Therapy and Diagnosis of Influenza - The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza A hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza A subtypes of subtype group 1 and 2, to vaccines and uses thereof. | 2014-12-18 |
20140370033 | METHODS FOR THE TREATMENT OR PREVENTION OF SYSTEMIC SCLEROSIS - The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular, fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention, therefore, relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced. | 2014-12-18 |
20140370034 | SDF-1 Binding Nucleic Acids and the Use Thereof - The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells. | 2014-12-18 |
20140370035 | METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY - The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain. | 2014-12-18 |
20140370036 | COMPOSITIONS OF, AND METHODS FOR, ALPHA-1 ANTITRYPSIN FcFUSION MOLECULES - A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), | 2014-12-18 |
20140370037 | DLL3 MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2014-12-18 |
20140370038 | CD4+ CD25+ T-CELLS ACTIVATED TO A SPECIFIC ANTIGEN - The invention relates to a method of assessing whether a subject includes CD4+,CD25+ T cells that have been activated to a specific antigen. The method includes the steps of obtaining from the subject a sample of lymphocytes including CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote, distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro. | 2014-12-18 |
20140370039 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 2014-12-18 |